Eli Lilly shares rose again Tuesday, their sixth increase in the past seven sessions. The drugmaker's market cap also closed ...

Eli Lilly shares have room to keep going as GLP-1 drugs spread their reach.

The benefits of SGLT2 inhibitors on kidney disease progression in individuals irrespective of diabetes or albuminuria status ...

Let’s delve into the details of each of the evaluated factors, but first, for a quick background: With a $917 Bil market cap, ...

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current ...

Eli Lilly's $2.6 billion agreement with ABL Bio focuses on developing therapeutics using the Grabody Platform for bispecific ...

The next generation of weight loss drugs will hit the market in 2026. Eli Lilly and Novo Nordisk are racing to the finish ...

As he discussed Amgen, it was unsurprising that weight loss drug giant Eli Lilly and Company (NYSE:LLY) also caught Cramer’s ...

Eli Lilly has received CDSCO approval for donanemab, an Alzheimer's treatment for adults in early symptomatic stages ...

Eli Lilly receives CDSCO approval for donanemab, a new Alzheimer's treatment targeting early symptomatic stages of the ...

Tuesday, November 18, 2025 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Microsoft ...

Investing.com -- Eli Lilly and Company (India) Pvt. has received marketing approval from India’s Central Drugs Standard Control Organization for donanemab, a medication used to treat Alzheimer’s ...